Targets › TFPI
2 programs from 2 companies in 6 trials: 5 Phase 3, 1 Phase 1; Hematology; next expected readout Feb 2027.
Inhibits factor X (X(a)) directly and, in a Xa-dependent way, inhibits VIIa/tissue factor activity, presumably by forming a quaternary Xa/LACI/VIIa/TF complex. It possesses an antithrombotic action and also the ability to associate with lipoproteins in plasma. (UniProt, P10646)
Open in Phaseline: the race on TFPI, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Novo Nordisk | Concizumab Tissue factor pathway inhibitor inhibitor | TFPI | Phase 3 | Haemophilia A With Inhibitors; Haemophilia A Without Inhibitors; Haemophilia A and B With and Without Inhibitors | Feb 2027 |
| Pfizer | marstacimab Tissue factor pathway inhibitor inhibitor | TFPI | Phase 3 | Hemophilia A; Severe Hemophilia A | May 2027 |
Hemophilia A (2) Severe Hemophilia A (1) Haemophilia A With Inhibitors (1) Haemophilia A Without Inhibitors (1) Haemophilia A and B With and Without Inhibitors (1)
antibody (2)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.